Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.7 (
plasmin
)
9,023
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Treatment of cultured bovine carotid artery endothelial cells with 10(-7) M
plasmin
increased arachidonate release coupled with the increase in prostacyclin production. The stimulatory effect of
plasmin
on arachidonate release could be divided into the early and late phases according to its calcium dependency and pertussis toxin sensitivity. The early phase of
plasmin
-induced arachidonate release was a calcium-dependent and pertussis toxin-sensitive response, which was observed within 20 min after
plasmin
treatment. The late phase was a calcium-independent and pertussis toxin-insensitive response, which was induced gradually from 20 to 60 min. Induction of the early phase of
plasmin
's effect required both the lysine binding and catalytic sites in
plasmin
molecule because it was inhibited either by the binding antagonist tranexamic acid or by the serine protease inhibitor aprotinin. Guanosine 5'-O-(2-thiotriphosphate) potentiated the effect of
plasmin
in permeabilized or nonpermeabilized cells, indicating that the early phase effect was mediated by a pertussis toxin-sensitive guanosine 5'-triphosphate (GTP)-binding protein. The late phase of
plasmin
's effect was due to the catalytic activity because it was inhibited by aprotinin but not by tranexamic acid. Microplasmin structurally having the catalytic sites induced a similar late phase effect. Plasmin did not elicit the metabolism of phosphatidyl polyphosphoinositides. These studies demonstrate that the activation of phospholipase A2, which results in arachidonate release, in the early phase of
plasmin
's effect is a receptor-mediation via
GTP-binding protein
that is not coupled through phospholipase C activation.
...
PMID:Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells. 838 26
Treatment of cultured bovine carotid artery endothelial cells with 0.1 &mgr;M human
plasmin
has been reported to induce a receptor-mediated short burst of arachidonate release, which is a pertussis toxin-sensitive and extracellular calcium-dependent reaction. Plasmin-induced calcium influx in cells was significantly inhibited by pretreatment with pertussis toxin, indicating that the former was coupled with a pertussis toxin-sensitive guanosine 5'-triphosphate (GTP)-binding protein. Plasmin significantly induced the formation of lysophosphatidylcholine but not lysophosphatidylethanolamine. A cellular phospholipase A(2) with an arachidonyl specificity at the sn-2 position of phosphatidylcholine, which required submicromolar calcium, was identified as a cytosolic phospholipase A(2) by immunoblot analysis. By a cell-free enzyme activity assay and immunoblot analysis,
plasmin
was found to induce a translocation of the cytosolic phospholipase A(2) from the cytosol to the membrane. Taken together, the results suggest that
plasmin
bound to its putative receptor and activated a
GTP-binding protein
coupled to calcium influx channel, followed by translocation and activation of cytosolic phospholipase A(2) in endothelial cells. Copyright 1996 S. Karger AG, Basel
...
PMID:Characterization of Phospholipase A(2) Activation by Plasmin in Cultured Bovine Endothelial Cells. 1172 84